Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group

A Sesen Bio investor group last month proposed an alternative to the Cambridge biotech’s planned merger with Carisma that it said would deliver "superior value" for the company’s stockholders. Now the group is on board with the deal.